TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05635877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol
Description: The treatment group was given Esmolol 0.5mg/kg load and 10μg /kg/min continuous pump

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Placebo Comparator:normal saline(0.9%)
Description: The control group received the same volume of 0.9% normal saline, which was continuously pumped until the end of the operation before extubation.Patient-controlled analgesia pump (sufentanil 2 μg/kg, 2 mL/h, for 48h) was used as the postoperative analgesia regimen in the two groups. If the VAS score was \>3, analgesic adjuvant drugs were given intravenously and recorded. If repeated treatment is ineffective, the study will be excluded.
Study: NCT05767164

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cervical single open-door surgery
Description: The patients were operated by the cervical single open-door surgery, which were used with the Centerpiece titanium plate to internal fixation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cervical single open-door surgery
Description: The patients were operated by the cervical single open-door surgery, which were used with the Centerpiece titanium plate to internal fixation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: cervical single open-door surgery
Description: The patients were operated by the cervical single open-door surgery, which were used with the Centerpiece titanium plate to internal fixation.
Study: NCT04885790

Intervention type: OTHER
Intervention: Respiratory assessment using Spiropalm 6MWT portable spirometry
Description: Spiropalm 6MWT portable spirometry will be used during six-minute walk test for evaluation of dynamic hyperinflation and other related ventilatory parameters. The device will also be used as regular spirometry.

Intervention type: OTHER
Intervention: Evaluation of functional exercise capacity
Description: Functional exercise capacity of patients will be evaluated using six-minute walk test.

Intervention type: OTHER
Intervention: Evaluation of peripheral muscle strength
Description: Handgrip strength and M. Quadriceps strength will be evaluated using hand-held dynamometer.

Intervention type: OTHER
Intervention: Evaluation of chronic cough
Description: The Leicester Cough Questionnaire will be used for evaluating cough.
Study: NCT06125158

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hip strength training
Description: Hip strength training required subjects to complete resistance training in hip abduction and posterior extension, anterior step-up and lateral step-up exercises with the help of elastic bands.
Study: NCT05327595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3549492
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3549492
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Administered orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam
Description: Administered orally.
Study: NCT06336811

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: passive virtual reality distraction
Description: watching the application by wearing virtual glasses to the child during the phlebotomy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active virtual reality distraction
Description: The remote control of the virtual glasses will be given to the hand, and the child will start, slow down or stop the application herself.
Study: NCT03377062

Intervention type: DIAGNOSTIC_TEST
Intervention: EEG monitoring
Description: Five-minute of EEG monitoring accompanied with auditory stimulation.
Study: NCT06125158

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Description: Neuromuscular electrical stimulation of the gluteus mediums and gluteus maximus muscles of the affected side was carried out using the TB6807 low-frequency therapeutic instrument (with prescription for neuromuscular electrical stimulation) manufactured by China Tangbang Science and Technology Company.
Study: NCT06248593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous infusion of Norepinephrine
Description: The rate of norepinephrine infusion will be adjusted according to values of systolic blood pressure measured noninvasively and recorded at 1-minute intervals along the intraoperative period, with the objective of maintaining values near baseline.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Continuous infusion of Phenylephrine
Description: The rate of phenylephrine infusion will be adjusted according to values of systolic blood pressure measured noninvasively and recorded at 1-minute intervals along the intraoperative period, with the objective of maintaining values near baseline.
Study: NCT06399991

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Champion strategy
Description: The champion strategy involves identifying champions within each district who are trained and supported as change agents through training and supervision.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Adapted LOCI leadership and climate alignment strategy plus champion strategy
Description: The LOCI strategy involves engaging with district health leadership through data and feedback, leadership development trainings, coaching, and alignment strategy activities to align leadership and climate in support of implementing the evidence-based mental health package. The champion strategy involves identifying champions within each district who are trained and supported as change agents through training and supervision.
Study: NCT04561778

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: HOT-CRT
Description: Subjects enrolled in the study will receive a permanent cardiac implantable electronic device (CIED) (CRT-pacemaker or CRT-defibrillator) as clinically indicated. Subjects randomized to HOT-CRT will have His bundle pacing lead placed initially to achieve CRT. If complete resynchronization is achieved (BBB normalization) but capture thresholds are high (1.5-2V), the lead may be placed in the distal conduction system (left bundle branch area). If only partial QRS narrowing is achieved, a coronary sinus lead may be placed and left ventricular timing may be optimized to achieve maximal resynchronization.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biventricular Pacing
Description: Subjects enrolled in the study will receive a permanent CIED (CRT-pacemaker or CRT-defibrillator) as clinically indicated. Subjects randomized to Biventricular pacing will undergo left ventricular lead placement in the coronary sinus venous branches.
Study: NCT05765201

Intervention type: OTHER
Intervention: High IOP
Description: Prospective, single-surgeon, randomized, paired-eye study; patients undergoing sequential, uncomplicated bilateral phacoemulsification using Active Sentry handpiece® with intraocular IOP ≤ 28mmHg (low IOP) in one eye and with IOP ≥ 60mmHg (high IOP) in the other eye

Intervention type: OTHER
Intervention: Low IOP
Description: Prospective, single-surgeon, randomized, paired-eye study; patients undergoing sequential, uncomplicated bilateral phacoemulsification using Active Sentry handpiece® with intraocular IOP ≤ 28mmHg (low IOP) in one eye and with IOP ≥ 60mmHg (high IOP) in the other eye
Study: NCT06265519

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Holmium laser enucleation of the prostate
Description: Holmium laser enucleation of the prostate is a minimally invasive procedure that uses pulses of laser beam to remove tissue from the inside of the prostate, which surrounds the urethra (the tube leading from the bladder to the urinary opening) in patients with BPH

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Holmium laser enucleation of the prostate
Description: Holmium laser enucleation of the prostate is a minimally invasive procedure that uses pulses of laser beam to remove tissue from the inside of the prostate, which surrounds the urethra (the tube leading from the bladder to the urinary opening) in patients with BPH
Study: NCT05388084

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Male peer engagement
Description: Male partners of women randomized to the intervention arm will receive a phone call from the male peer to encourage them to test for HIV at the clinic. Male peer fathers will offer to meet men at the clinic and guide them through the process of HIV testing. Men who are not willing/able to attend the clinic for HIV testing will be offered testing in a private and confidential location in the community; the peer male counselor meet men and offer to assist them through the process of using and interpreting an oral HIVST. Men who are not interested in testing with the peer father will be offered the HIVST kit to take home. Peer fathers will obtain men's consent to participate in the study.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SOC and delayed intervention
Description: Females receive standard of care invitation letter to provide to their partner for fast-track HIV testing and male peer father phone calls after a 3 month delay.
Study: NCT04862975

Intervention type: DRUG
Intervention: Dolutegravir
Description: Dolutegravir will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. Not prescribed for this study.

Intervention type: DRUG
Intervention: Lamivudine
Description: Lamivudine will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. Not prescribed for this study.

Intervention type: DRUG
Intervention: Emtricitabine
Description: Emtricitabine will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. Not prescribed for this study.

Intervention type: DRUG
Intervention: Tenofovir Disoproxil Fumarate
Description: Tenofovir Disoproxil Fumarate will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. Not prescribed for this study.
Study: NCT04456400

Intervention type: DIAGNOSTIC_TEST
Intervention: Multispectral Optoacoustic Tomography (MSOT)
Description: cMSOT-2 system is indicated for measurement of the Multispectral Optoacoustic Tomography (MSOT) values in the bowel wall of patients with an established diagnosis of inflammatory bowel disease (IBD), specifically Crohn's Disease (CD) and Ulcerative Colitis (UC). The MSOT values provided may be used as an aid to the assessment of inflammatory disease activity in the bowel wall.

Intervention type: DIAGNOSTIC_TEST
Intervention: Multispectral Optoacoustic Tomography (MSOT)
Description: cMSOT-2 system is indicated for measurement of the Multispectral Optoacoustic Tomography (MSOT) values in the bowel wall of patients with an established diagnosis of inflammatory bowel disease (IBD), specifically Crohn's Disease (CD) and Ulcerative Colitis (UC). The MSOT values provided may be used as an aid to the assessment of inflammatory disease activity in the bowel wall.
Study: NCT05765071

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum toxin A
Description: Botulinum injections will be prepared by diluting 100 units of botulinum toxin A with 5.0mL of saline (20.0U/mL). A total of 100 units (5.0mL) of botulinum toxin A will be injected into the tibialis anterior, peroneus longus and peroneus brevis muscles of the affected leg. Under ultrasound guidance, the injectant will be deposited at two sites in each muscle near the motor points.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: A total of 5.0mL of normal saline will be injected into the tibialis anterior, peroneus longus and peroneus brevis muscles of the affected leg. Under ultrasound guidance, the injectant will be deposited at two sites in each muscle near the motor points.
Study: NCT06101888

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TaurusTrio™ Heart Valve System
Description: The TaurusTrio™ Heart Valve System contains the following sub-components: a prosthetic transcatheter porcine pericardial aortic valve, 20Fr Introducer Sheath System, transfemoral Delivery Catheter, and Loading Tool.
Study: NCT05176639

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veligrotug (VRDN-001) Phase 1/2 MAD (HV and TED)
Description: 2 IV Infusions of multiple ascending doses of veligrotug (VRDN-001), ranging from 3 mg/kg to 20 mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRDN-001 Phase 3 Cohort (THRIVE)
Description: 5 IV Infusions of veligrotug (VRDN-001) 10mg/kg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VRDN-001 Placebo
Description: 5 IV Infusions of veligrotug (VRDN-001) placebo
Study: NCT05961189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Standard of care, 5 days of drug per manufacturer's instructions.
Study: NCT04766190

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Group 2: The DISCO App
Description: Patients will receive an individually-tailorable cancer treatment cost education and communication intervention delivered on an iPad just prior to meeting with their oncologist.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Group 1: Usual Care
Description: Patients randomized to this arm will receive usual care.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Group 3: The DISCO App + Booster
Description: Patients will receive an individually-tailorable cancer treatment cost education and communication intervention delivered on an iPad just prior to meeting with their oncologist. Then, 2 months later they will receive an intervention booster in the form of an individually-tailored email to remind patients of the contents of the intervention.
Study: NCT04831879

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GONDOLA AMPS
Description: The Gondola device is composed of two units, one per foot, each having two motors that activate rounded stimulation tips that interact with the target points. It delivers mechanical, pressure-based stimulations, sequentially in each of the four points, for the duration of 6 seconds per point. This treatment cycle is repeated 4 times, for an overall treatment duration of less than 2 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GONDOLA AMPS
Description: The Gondola device is composed of two units, one per foot, each having two motors that activate rounded stimulation tips that interact with the target points. It delivers mechanical, pressure-based stimulations, sequentially in each of the four points, for the duration of 6 seconds per point. This treatment cycle is repeated 4 times, for an overall treatment duration of less than 2 minutes
Study: NCT05393089

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGN-190584
Description: Eye drops

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Eye drops
Study: NCT06508892

Intervention type: BEHAVIORAL
Intervention: risk of fall
Description: Gather information that will assist in determining risk of fall. The researchers will ask the subjects to perform several motor tests and study-related questionnaires.
Study: NCT06430229

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Volume controlled ventilation (VCV) mode
Description: Patients to be ventilated with VCV mode were placed on respiratory support (Dräger Primus) with a breathing rate that would provide 8 ml/kg tidal volume, 5 cmH2O PEEP, and 30-35 mmHg end-tidal carbon dioxide concentration (etCO2) level.~Lung ultrasonography was performed at 4 different time periods (before laryngeal mask airway (LMA), at the 10th minute after LMA, before extubation and at the 10th minute after extubation). Modified lung ultrasonography scores of 12 quadrants were recorded.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pressure controlled ventilation (PCV) mode
Description: Appropriate peak inspiratory pressure was set to create a tidal volume of 8 ml/kg in patients who would be ventilated with PCV mode. The number of breaths (Dräger Primus) was adjusted to provide an end-tidal carbon dioxide concentration (etCO2) level of 30-35 mmHg. PEEP was set to 5 cmH2O.~Lung ultrasonography was performed at 4 different time periods (before laryngeal mask airway (LMA), at the 10th minute after LMA, before extubation and at the 10th minute after extubation). Modified lung ultrasonography scores of 12 quadrants were recorded.
Study: NCT05368155

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief ACT for Pelvic Pain
Description: The Brief ACT for Pelvic Pain treatment will include three weekly, 90-minute group sessions that teach Veterans new ways to respond to difficult thoughts and emotions related to pain (Acceptance and Mindfulness Training) and encourage behavioral (re)engagement in meaningful life activities (Behavioral Change Training). The overall goal is to cultivate psychological flexibility by helping Veterans learn to respond to life events in ways which do not exacerbate difficulties or restrict engagement in meaningful activities. Workshop content is integrated with education on pelvic pain (its diagnostic criteria, etiology, and associated health outcomes) to increase alignment of the treatment with patient needs.
Study: NCT06445400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BL-M07D1
Description: Administration by intravenous infusion for a cycle of 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Administration by intravenous infusion for a cycle of 3 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Administration by intravenous infusion for a cycle of 3 weeks.
Study: NCT06413953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TQB3107 Tablets
Description: TQB3107 tablets is protein inhibitor that inhibit tumor cell proliferation, and induce apoptosis, thereby exerting anti-tumor effects.
Study: NCT03653000

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided brachial plexus blockade
Description: Ultrasound probe disposed on the shoulder, on the deltoid muscle. in plane puncture toward the brachial artery and injection of local anaesthetics around the brachial artery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: local anaesthetic injection
Description: Local anesthetic injection (ropivacaine) at this new site
Study: NCT04906265

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intervention
Description: The intervention comprises of standard rehabilitation and continuous measures of body positions and movements 24 hour a day with an IMU. Standard rehabilitation comprises of home-visits by a PT, where an individualized rehabilitation plan is outlined together with the patient. The plan includes individually tailored functional exercises. The plan also includes individually tailored walking exercises, indoor and outdoor when possible. At each home visit, the PT provides feedback to the participant based on the data from the IMU, i.e. body positions (time spent in sitting, standing, lying down) and body movements (steps per day, step length, walking speed, sideway deviation during walking)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard rehabiliation
Study: NCT05068011

Intervention type: DEVICE
Intervention: Spinal Cord Stimulation
Description: differential target multiplexed stimulation
Study: NCT06224296

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DFPP
Description: One session of blood purification using DFPP to remove inflammatory cytokines in peripheral blood.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DFPP
Description: One session of blood purification using DFPP to remove lipids in peripheral blood.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DFPP
Description: One session of blood purification using DFPP to remove toxic metal ions.
Study: NCT06049368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-P16-093
Description: Intravenous injection of 68Ga-P16-093 with the dosage of 1.5-1.8 MBq (0.04-0.05 mCi)/kg. Tracer doses of 68Ga-P16-093 will be used to image lesions of glioma by PET/CT.
Study: NCT05223218

Intervention type: OTHER
Intervention: Schirmer strip, a Class I Medical Device typically used to test for dry eye.
Description: Schirmer strip is a Class I Medical Device typically used to test for dry eye and will be used to collect lacrimal tear fluids.

Intervention type: OTHER
Intervention: Schirmer strip, a Class I Medical Device typically used to test for dry eye.
Description: Schirmer strip is a Class I Medical Device typically used to test for dry eye and will be used to collect lacrimal tear fluids.

Intervention type: OTHER
Intervention: Schirmer strip, a Class I Medical Device typically used to test for dry eye.
Description: Schirmer strip is a Class I Medical Device typically used to test for dry eye and will be used to collect lacrimal tear fluids.

Intervention type: OTHER
Intervention: Schirmer strip, a Class I Medical Device typically used to test for dry eye.
Description: Schirmer strip is a Class I Medical Device typically used to test for dry eye and will be used to collect lacrimal tear fluids.

Intervention type: OTHER
Intervention: Schirmer strip, a Class I Medical Device typically used to test for dry eye.
Description: Schirmer strip is a Class I Medical Device typically used to test for dry eye and will be used to collect lacrimal tear fluids.

Intervention type: OTHER
Intervention: Schirmer strip, a Class I Medical Device typically used to test for dry eye.
Description: Schirmer strip is a Class I Medical Device typically used to test for dry eye and will be used to collect lacrimal tear fluids.
Study: NCT05194033

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics daily
Description: Probiotics 1 time/day for 7 consecutive days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo daily
Description: Placebo 1 time/day for 7 consecutive days
Study: NCT06106542

Intervention type: OTHER
Intervention: assessment
Description: assessment of motor imagery on muscle oxygenation